c-Myc tag Peptide: Specific Displacement Tool for Immunoassays and Cancer Research

Executive Summary: The c-Myc tag Peptide (SKU: A6003) is a synthetic peptide corresponding to amino acids 410–419 of human c-Myc, used primarily for displacing c-Myc-tagged fusion proteins from anti-c-Myc antibodies in immunoassays. This reagent enables precise study of c-Myc's role as a transcription factor regulating cell proliferation and apoptosis (Wu et al., 2021). Mechanistically, c-Myc activation upregulates cyclins and ribosomal genes, while repressing cell cycle inhibitors and anti-apoptotic factors. The peptide displays high solubility in DMSO (≥60.17 mg/mL) and moderate solubility in water (≥15.7 mg/mL with ultrasonication), but is insoluble in ethanol. APExBIO supplies this reagent for non-diagnostic scientific research, addressing critical needs in cancer and transcription factor studies.

Biological Rationale

The c-Myc protein is a proto-oncogene that encodes a transcription factor involved in diverse cellular processes including cell growth, proliferation, apoptosis, differentiation, and stem cell renewal (Wu et al., 2021). Its dysregulation is linked to tumorigenesis in multiple cancer types. The C-terminal region (amino acids 410–419) is crucial for antibody recognition and protein-protein interaction studies. Synthetic c-Myc tag Peptides mimic this region, enabling specific modulation and detection of c-Myc activity in molecular and cell biology experiments. The peptide is widely adopted in research settings to aid in the displacement of c-Myc-tagged fusion proteins, allowing for the study of downstream signaling and protein complex formation (see also: Harnessing c-Myc tag Peptide for Precision Immunoassays; this article expands on benchmarked solubility and protocol considerations beyond the scope of the linked review).

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide operates as a competitive inhibitor in immunoassays. It binds specifically to anti-c-Myc antibodies, thereby displacing c-Myc-tagged fusion proteins from the antibody complex. This capacity is essential for elution in immunoprecipitation workflows and for validating antibody specificity (APExBIO Product Page). The myc tag sequence (EQKLISEEDL) corresponds to residues 410–419 of human c-Myc. This sequence is recognized by several commercial monoclonal antibodies, including clone 9E10. By providing a defined and saturating concentration of the synthetic peptide, researchers can inhibit antibody binding to the fusion protein, thus enabling elution or specificity testing (c-Myc tag Peptide: A Molecular Tool for Precision Regulation; this article provides additional mechanistic insights into transcription factor modulation not covered here).

Evidence & Benchmarks

• c-Myc tag Peptide displaces c-Myc-tagged fusion proteins from anti-c-Myc antibodies in immunoprecipitation and ELISA protocols (APExBIO Product Data).
• Human c-Myc protein regulates cell proliferation, apoptosis, and differentiation by upregulating cyclins and downregulating p21 and Bcl-2 (Wu et al., 2021).
• The peptide is soluble at ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (ultrasonication required), but insoluble in ethanol (APExBIO Product Data).
• Storage at -20°C (desiccated) is required for long-term stability; solutions are not recommended for extended storage (APExBIO Product Data).
• IRF3, another key transcription factor, is activated by C-terminal phosphorylation clusters, drawing a parallel to c-Myc's functional regulation (Wu et al., 2021).

Applications, Limits & Misconceptions

Main Applications:

• Displacement of c-Myc-tagged fusion proteins in immunoprecipitation and ELISA workflows (APExBIO Product Page).
• Specific inhibition of anti-c-Myc antibody binding for assay validation and control experiments (Applied Strategies with c-Myc Peptide; this article details troubleshooting not addressed in the present review).
• Research into c-Myc mediated gene amplification and transcriptional regulation in cancer biology (c-Myc tag Peptide: Systems Biology Insights for Cancer and Immunology; this article covers systems-level implications beyond the primary biochemical focus here).

Common Pitfalls or Misconceptions

• Not suitable for diagnostic or clinical use; for research purposes only.
• Ineffective in ethanol due to insolubility—DMSO or water (with ultrasonication) are required solvents.
• Prolonged storage of peptide solutions leads to degradation and loss of activity; always prepare fresh solutions.
• The peptide does not directly modulate endogenous c-Myc transcriptional activity in live cells; it functions as a competitive inhibitor in vitro.
• Displacement activity is concentration-dependent and may require optimization for different assay formats.

Workflow Integration & Parameters

For immunoprecipitation, add the synthetic c-Myc tag Peptide at a final concentration sufficient to saturate anti-c-Myc antibody binding sites (commonly 1–10 μg/mL, but optimization is required). Use DMSO (≥60.17 mg/mL) for stock solutions, or water (≥15.7 mg/mL) with ultrasonication if DMSO is not compatible with the assay. Avoid ethanol as the peptide is insoluble. Store lyophilized peptide desiccated at -20°C. Prepare fresh working solutions immediately prior to use to ensure maximal activity. For antibody specificity validation, include the peptide in parallel control reactions. To extend protocol robustness, see additional troubleshooting guidance in Harnessing c-Myc tag Peptide for Precision Immunoassays.

Conclusion & Outlook

The c-Myc tag Peptide (from APExBIO) is a well-characterized, high-purity research reagent enabling precise modulation of antibody-protein interactions in immunoassays and advancing studies of proto-oncogene c-Myc function. Its defined sequence and solubility profile facilitate reproducible workflows. As research into transcription factor regulation and cancer biology progresses, the peptide remains an indispensable tool for dissecting c-Myc-mediated mechanisms and validating assay specificity (Wu et al., 2021).